CORC

浏览/检索结果: 共6条,第1-6条 帮助

限定条件                
已选(0)清除 条数/页:   排序方式:
Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文
JAMA oncology, 2018, 卷号: 4, 页码: 1569-1575
作者:  Han Baohui;  Li Kai;  Wang Qiming;  Zhang Li;  Shi Jianhua
收藏  |  浏览/下载:5/0  |  提交时间:2019/11/26
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文
CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 页码: 443-451
作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua
收藏  |  浏览/下载:5/0  |  提交时间:2019/11/26
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文
LUNG CANCER, 2018, 卷号: 122, 页码: 32-37
作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao
收藏  |  浏览/下载:3/0  |  提交时间:2019/11/26
A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 页码: S886-S887
作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li
收藏  |  浏览/下载:9/0  |  提交时间:2019/11/26
Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study 期刊论文
LANCET ONCOLOGY, 2017, 卷号: 18, 页码: S3-S3
作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhao, Yizhuo;  Zhang, Li
收藏  |  浏览/下载:10/0  |  提交时间:2019/11/26
PHACTR1 and SLC22A3 gene polymorphisms are associated with reduced coronary artery disease risk in the male Chinese Han population 期刊论文
ONCOTARGET, 2017, 卷号: 8, 页码: 658-663
作者:  Zhao, Qingbin;  Wei, Huiyi;  Liu, Dandan;  Shi, Baolan;  Li, Lei
收藏  |  浏览/下载:19/0  |  提交时间:2019/11/26


©版权所有 ©2017 CSpace - Powered by CSpace